129 related articles for article (PubMed ID: 2860683)
1. Amphetamine response and relapse risk after depot neuroleptic discontinuation.
Angrist B; Peselow E; Rubinstein M; Wolkin A; Rotrosen J
Psychopharmacology (Berl); 1985; 85(3):277-83. PubMed ID: 2860683
[TBL] [Abstract][Full Text] [Related]
2. A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. A clinical and experimental-psychological study.
Cesarec Z; Eberhard G; Nordgren L
Acta Psychiatr Scand Suppl; 1974; 249():65-77. PubMed ID: 4608707
[No Abstract] [Full Text] [Related]
3. L-dopa challenge and relapse in schizophrenia.
Davidson M; Keefe RS; Mohs RC; Siever LJ; Losonczy MF; Horvath TB; Davis KL
Am J Psychiatry; 1987 Jul; 144(7):934-8. PubMed ID: 2886063
[TBL] [Abstract][Full Text] [Related]
4. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
[TBL] [Abstract][Full Text] [Related]
5. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects.
Angrist B; Rotrosen J; Gershon S
Psychopharmacology (Berl); 1980 Jan; 67(1):31-8. PubMed ID: 6102776
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
[No Abstract] [Full Text] [Related]
7. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
Woggon B; Bickel P; Schnyder B
Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
[TBL] [Abstract][Full Text] [Related]
8. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
9. How schizophrenic patients change during 3 years' treatment with depot neuroleptics.
Dencker SJ; Frankenberg K; Lepp M; Lindberg D; Malm U
Acta Psychiatr Scand; 1978 Feb; 57(2):115-23. PubMed ID: 24982
[TBL] [Abstract][Full Text] [Related]
10. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
[TBL] [Abstract][Full Text] [Related]
11. Lowest effective dose of depot neuroleptics.
Hoencamp E; Haffmans PJ; Jansen GS
Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
[No Abstract] [Full Text] [Related]
12. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
[TBL] [Abstract][Full Text] [Related]
13. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.
Weiden P; Rapkin B; Zygmunt A; Mott T; Goldman D; Frances A
Psychiatr Serv; 1995 Oct; 46(10):1049-54. PubMed ID: 8829787
[TBL] [Abstract][Full Text] [Related]
14. Low-dose depot medication in schizophrenia.
Burnett PL; Galletly CA; Moyle RJ; Clark CR
Schizophr Bull; 1993; 19(1):155-64. PubMed ID: 8095736
[TBL] [Abstract][Full Text] [Related]
15. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study.
Dencker SJ; Lepp M; Malm U
Acta Psychiatr Scand Suppl; 1980; 279():64-76. PubMed ID: 6105763
[TBL] [Abstract][Full Text] [Related]
16. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
Steingard S; Allen M; Schooler NR
J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
[TBL] [Abstract][Full Text] [Related]
18. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
19. Reducing the dose of depot neuroleptics in stable schizophrenia.
Dale R; Longdon M; Seeman MV
J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
[TBL] [Abstract][Full Text] [Related]
20. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Walker CA
Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
